|
|
Article: XOMA Terminates $73M BPI Deal With Zephyr Sciences.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Only eight months after Zephyr Sciences Inc. in-licensed Neuprex and related bactericidal/permeability-increasing protein (BPI) products, XOMA Ltd. decided to terminate the agreement, because Zephyr had not met its financial requirements.
The potential $73 million deal signed in November gave new hope for Neuprex, a product developed for several indications but one that has hit roadblocks along the way, including a pullout by partner Baxter Healthcare Corp.
Despite a second terminated deal, this time with Zephyr, XOMA remains focused on its BPI products, stressing their excellent safety profiles in pediatric and adult indications.
Related newspaper, magazine, and journal articles:
|